On June 2, 2025, uniQure shared that they’re aligned with the FDA about moving forward with their HTT-lowering gene therapy, AMT‑130. If the next round of results from their ongoing trial continues to ...

The brain has plans in place when fires break out. Normally, a molecule called PKD1 rushes in to the rescue, but in ...

To date, the GeM-HD consortium has studied thousands of people with HD and hundreds of thousands of spelling changes in every ...

One common, but lesser-understood symptom of HD is irritability. Irritability can be deeply distressing for the person with ...

Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.

Spark and Roche issued a joint community letter to share that the first patient has been dosed in a new HD gene therapy trial. To capture your interest with a romance, let’s talk about how these ...

DNA-based drugs called antisense oligonucleotides, or ASOs, are now in multiple clinical trials in Huntington’s disease, aiming to lower production of the harmful mutant huntingtin protein in the ...

This week, we heard an update from Roche about their huntingtin-lowering therapy, tominersen, currently being tested in the GENERATION HD2 trial. An independent data monitoring committee (iDMC) that ...